SCHEMBL2279156

SCHEMBL2279156

CCOC1CCC(N2CCC(Nc3cc(C)cc(F)c3N)CC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.39
CHRM4 P08173 2/20 0.39
CHRM5 P08912 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM3 P20309 2/20 0.39
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
MAPK10 P53779 1/20 0.32
IRAK4 Q9NWZ3 4/20 0.32
EHMT2 Q96KQ7 3/20 0.32
NSD2 O96028 2/20 0.32
BRD4 O60885 1/20 0.31
ATAD2 Q6PL18 1/20 0.31
ALOX15 P16050 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
DNMT1 P26358 2/20 0.31
EHMT1 Q9H9B1 1/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279157 1.00 CHRM2 (0.39) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2282417 0.92 CHRM2 (0.33) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2277732 0.92 CHRM2 (0.33) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2272619 0.88 PIK3CA (0.34) IRAK4EHMT2NSD2BRD4ATAD2
SCHEMBL2277492 0.88 PIK3CA (0.34) IRAK4EHMT2NSD2BRD4ATAD2
SCHEMBL2272620 0.88 PIK3CA (0.34) IRAK4EHMT2NSD2BRD4ATAD2
SCHEMBL12405218 0.86 CHRM1 (0.37) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL14413637 0.84 CHRM4 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2280175 0.84 CHRM4 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2274955 0.84 CHRM4 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996189-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2012-09-26 EP disclosed
US-20110207777-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE TELECOM IP LIMITED 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207777-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 CHRM2 2/4885CHRM4 3/4885CHRM5 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.